Breaking Finance News

Lipocine (NASDAQ:LPCN) target price raised to $25.00, reported today by H.C. Wainwright

Lipocine (NASDAQ:LPCN) had its target price raised to $25.00 by H.C. Wainwright in a report released 10/07/2016. The new stock price target indicates a possible upside of 5.00% based on the company's last closing price.

Previously on Tuesday June 23, 2015, Canaccord Genuity reported on Lipocine (NASDAQ:LPCN) increased the target price from $0.00 to $15.00. At the time, this indicated a possible upside of 0.86%.

Just yesterday Lipocine (NASDAQ:LPCN) traded -3.02% lower at $4.17. Lipocine’s 50-day average is $3.75 and its two hundred day average is $6.55. The last stock price is down -36.35% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Trade Volume was down over the average, with 119,978 shares of LPCN changing hands under the typical 233,865

Recent Performance Chart

Lipocine (NASDAQ:LPCN)

Lipocine has 52 week low of $2.51 and a 52 week high of $14.80 and has a market cap of $0.

General Information About Lipocine (NASDAQ:LPCN)

Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *